Moreover, we seek to determine the impact of co-targeted PIM and PI3K treatment on mRNA and phosphoprotein expression in prostate cancer cell models and ex vivo cultured prostate cancer tissue, as compared to targeting a single pathway. The gene discussed is PIK3CG; the disease is Familial prostate cancer.